Literature DB >> 12231537

The paradoxical expression of maspin in ovarian carcinoma.

Anil K Sood1, Mavis S Fletcher, Lynn M Gruman, Jeremy E Coffin, Sarvenaz Jabbari, Zhila Khalkhali-Ellis, Nancy Arbour, Elisabeth A Seftor, Mary J C Hendrix.   

Abstract

Maspin is a noninhibitory member of the serpin family that is down-regulated in breast carcinoma but overexpressed in pancreatic carcinoma. There are no published data regarding the role of maspin in ovarian carcinoma, which is the focus of the present study. Ovarian cell lines (normal and cancer) and tumors (80 invasive, 14 benign, and 10 low malignant potential) were evaluated for maspin expression and localization. Normal ovarian surface epithelial cells had low levels of maspin. Two of four ovarian cancer cell lines (OVCAR3 and SKOV3) expressed maspin, whereas the cell line EG had weak expression, and 222 had no detectable maspin. Subcellular fractionation studies revealed that the two maspin-positive ovarian cancer cell lines contained maspin in both the nuclear and cytosolic compartments. Wild-type maspin was transfected into the aggressive ovarian cancer cell lines SKOV3 and 222. The in vitro invasive activity of the maspin-transfected cell lines was 44-68% lower than respective controls. The histopathology analysis revealed that among the ovarian tumors examined, 57 (71%) were ranked positive for maspin. Thirty (37%) of the invasive tumors overexpressed maspin. Invasive cancers were more likely to have predominantly cytoplasmic staining compared with benign and low-malignant-potential tumors. Maspin overexpression was significantly associated with a high tumor grade (P = 0.004), the presence of ascites (P = 0.02), a lower likelihood of optimal surgical cytoreduction (P = 0.04), and a shorter duration of overall survival (median survival, 6.33 versus 2.67 years; P = 0.003). The Cox proportional hazards multivariate model revealed that maspin overexpression and high stage were independent predictors of survival. Thus, maspin was found to be overexpressed in a substantial proportion of ovarian tumors, which may serve as an adverse prognostic factor; however, its localization may provide new clues as to its activity and function. These paradoxical results may offer new insights regarding the role of maspin in ovarian cancer progression that may also impact diagnosis and treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12231537

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  59 in total

1.  Aberrant methylation of the maspin promoter is an early event in human breast cancer.

Authors:  Bernard W Futscher; Megan M O'Meara; Christina J Kim; Margaret A Rennels; Di Lu; Lynn M Gruman; Richard E B Seftor; Mary J C Hendrix; Frederick E Domann
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

2.  Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition.

Authors:  Khatri Latha; Weiguo Zhang; Nathalie Cella; Heidi Y Shi; Ming Zhang
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

3.  Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation.

Authors:  M Margarida Bernardo; Yonghong Meng; Jaron Lockett; Gregory Dyson; Alan Dombkowski; Alexander Kaplun; Xiaohua Li; Shuping Yin; Sijana Dzinic; Mary Olive; Ivory Dean; David Krass; Kamiar Moin; R Daniel Bonfil; Michael Cher; Wael Sakr; Shijie Sheng
Journal:  Genes Cancer       Date:  2011-11

4.  Expression of maspin is associated with the intestinal type of gastric adenocarcinoma.

Authors:  Seong Man Kim; Seong Jin Cho; Woo Young Jang; Duck Hwan Kim; Hyung Sik Shin; Myoung Kuk Jang; Hak Yang Kim; Eun Sook Nam
Journal:  Cancer Res Treat       Date:  2005-08-31       Impact factor: 4.679

5.  Maspin expression in gastrointestinal stromal tumors.

Authors:  Saduman Balaban Adim; Gulaydan Filiz; Ozkan Kanat; Omer Yerci; Halil Ozguc; Berna Aytac
Journal:  World J Surg Oncol       Date:  2010-03-26       Impact factor: 2.754

6.  Clinicopathological significance of maspin expression in breast cancer.

Authors:  Mi Ja Lee; Chae Hong Suh; Zhu-Hu Li
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

7.  Epigenetic silencing of maspin expression occurs early in the conversion of keratocytes to fibroblasts.

Authors:  Mark A Horswill; Malathi Narayan; Debra J Warejcka; Lisa A Cirillo; Sally S Twining
Journal:  Exp Eye Res       Date:  2008-01-12       Impact factor: 3.467

8.  Prognostic significance of the maspin tumor suppressor gene in pulmonary adenocarcinoma.

Authors:  Masanao Nakashima; Nobuyuki Ohike; Koichi Nagasaki; Mitsuru Adachi; Toshio Morohoshi
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-12       Impact factor: 4.553

9.  Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer.

Authors:  Mario W Kramer; Sandra Waalkes; Jörg Hennenlotter; Jürgen Serth; Arnulf Stenzl; Markus A Kuczyk; Axel S Merseburger
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

10.  Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control.

Authors:  Matthew Fitzgerald; Marc Oshiro; Nicholas Holtan; Kimberly Krager; Joseph J Cullen; Bernard W Futscher; Frederick E Domann
Journal:  Neoplasia       Date:  2003 Sep-Oct       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.